Market Closed -
Nyse
04:10:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
2.76
USD
|
+9.06%
|
|
+3.56%
|
-14.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
32.29
|
55.82
|
148.4
|
44.82
|
117.1
|
99.77
|
-
|
-
|
Enterprise Value (EV)
1 |
32.29
|
55.82
|
148.4
|
44.82
|
117.1
|
99.77
|
99.77
|
99.77
|
P/E ratio
|
-1.31
x
|
-2.21
x
|
-5.71
x
|
-1.15
x
|
-1.7
x
|
-2.07
x
|
-2.12
x
|
-2.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
67.8
x
|
33.2
x
|
8.14
x
|
25.9
x
|
21.5
x
|
36.3
x
|
-
|
EV / Revenue
|
-
|
67.8
x
|
33.2
x
|
8.14
x
|
25.9
x
|
21.5
x
|
36.3
x
|
-
|
EV / EBITDA
|
-1.75
x
|
-2.73
x
|
-6.55
x
|
-1.24
x
|
-2.93
x
|
-2.11
x
|
-1.86
x
|
-
|
EV / FCF
|
-2,054,762
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,934
|
18,702
|
27,086
|
36,145
|
36,147
|
36,149
|
-
|
-
|
Reference price
2 |
3.250
|
2.985
|
5.480
|
1.240
|
3.240
|
2.760
|
2.760
|
2.760
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.823
|
4.474
|
5.508
|
4.529
|
4.64
|
2.75
|
-
|
EBITDA
1 |
-18.4
|
-20.47
|
-22.65
|
-36.05
|
-39.92
|
-47.2
|
-53.6
|
-
|
EBIT
1 |
-19.75
|
-21.59
|
-23.82
|
-36.95
|
-40.89
|
-46.66
|
-64.76
|
-91.87
|
Operating Margin
|
-
|
-2,622.96%
|
-532.45%
|
-670.77%
|
-902.85%
|
-1,005.64%
|
-2,354.78%
|
-
|
Earnings before Tax (EBT)
1 |
-19.48
|
-22.18
|
-23.16
|
-36.92
|
-69.04
|
-49.25
|
-63.54
|
-98.33
|
Net income
1 |
-19.48
|
-22.18
|
-23.16
|
-36.92
|
-69.04
|
-49.25
|
-63.54
|
-98.33
|
Net margin
|
-
|
-2,695.14%
|
-517.55%
|
-670.24%
|
-1,524.51%
|
-1,061.42%
|
-2,310.69%
|
-
|
EPS
2 |
-2.490
|
-1.350
|
-0.9600
|
-1.080
|
-1.910
|
-1.335
|
-1.300
|
-1.040
|
Free Cash Flow
|
-15.71
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.03
|
1.251
|
0.989
|
1.236
|
1.883
|
1.338
|
1.051
|
0.796
|
0.98
|
1.225
|
1.528
|
1.136
|
1.152
|
1.168
|
1.185
|
-
|
EBITDA
1 |
-
|
-
|
-5.77
|
-8.549
|
-
|
-8.397
|
-10.08
|
-11.12
|
-9.401
|
-10.12
|
-9.286
|
-10.2
|
-11.1
|
-12.1
|
-13.8
|
-
|
EBIT
1 |
-9.51
|
-6.143
|
-6.047
|
-8.775
|
-9.22
|
-8.623
|
-10.33
|
-11.35
|
-9.629
|
-10.34
|
-9.579
|
-10.9
|
-11.39
|
-11.74
|
-12.1
|
-12.19
|
Operating Margin
|
-31,700%
|
-491.05%
|
-611.43%
|
-709.95%
|
-489.64%
|
-644.47%
|
-982.78%
|
-1,425.38%
|
-982.55%
|
-843.76%
|
-626.9%
|
-959.67%
|
-989.06%
|
-1,004.97%
|
-1,021.01%
|
-
|
Earnings before Tax (EBT)
1 |
-9.79
|
-5.419
|
-6.047
|
-8.774
|
-9.215
|
-8.614
|
-10.32
|
-14.49
|
-3.547
|
-31.16
|
-19.85
|
-11.2
|
-11.9
|
-12.6
|
-13.6
|
-13.75
|
Net income
1 |
-9.79
|
-5.419
|
-6.047
|
-8.774
|
-9.215
|
-8.614
|
-10.32
|
-14.49
|
-3.547
|
-31.16
|
-19.85
|
-11.2
|
-11.9
|
-12.6
|
-13.6
|
-13.75
|
Net margin
|
-32,633.33%
|
-433.17%
|
-611.43%
|
-709.87%
|
-489.38%
|
-643.8%
|
-981.45%
|
-1,820.35%
|
-361.94%
|
-2,543.76%
|
-1,298.89%
|
-986%
|
-1,033.52%
|
-1,078.68%
|
-1,147.97%
|
-
|
EPS
2 |
-0.6800
|
-0.2200
|
-0.2300
|
-0.3000
|
-0.2600
|
-0.2400
|
-0.2900
|
-0.4000
|
-0.1000
|
-0.8600
|
-0.5500
|
-0.3100
|
-0.3200
|
-0.3350
|
-0.3600
|
-0.3100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/13/20
|
11/10/21
|
3/17/22
|
5/12/22
|
8/11/22
|
11/9/22
|
3/16/23
|
5/11/23
|
8/14/23
|
11/14/23
|
3/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-15.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.13
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
2.76
USD Average target price
8
USD Spread / Average Target +189.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.81% | 99.77M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|